Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hôpital de Braine-l'Alleud | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study compares intrathecal 1% plain chloroprocaine with intrathecal 2% hyperbaric prilocaine for patients undergoing ambulatory knee arthroscopy in terms of efficacy and side effects
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Isobaric 2-chloroprocaine | Active Comparator | The 50 mg dose of isobaric 2-chloroprocaine will be administered to patients undergoing ambulatory knee arthroscopy |
|
| Hyperbaric prilocaine 2% | Active Comparator | The dose of 50 mg of Hyperbaric prilocaine 2% will be administered to patients undergoing ambulatory knee arthroscopy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Isobaric 2-chloroprocaine | Drug | intrathecal injection of 50 mg isobaric 2-Chloroprocaine |
|
| Measure | Description | Time Frame |
|---|---|---|
| Duration of sensory block | Total duration of sensory block is the interval time between the end of intrathecal injection and the complete recovery of sensory block | Until complete release of sensory block |
| Measure | Description | Time Frame |
|---|---|---|
| Onset time of sensory block | The levels of sensory block will be determined at 5, 10, 20 and 30 minutes after intrathecal injection. The levels of sensory block will be assessed as loss of sensation to pin-prick and cold. | up to 30 minutes |
| Onset time of motor block |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Emmanuel Guntz, MD | Université Libre de Bruxelles (ULB), Braine-l'Alleud Hospital | Study Director |
| Panayota Kapessidou, MD,PhD | University Hospital Saint-Pierre (CHU Saint-Pierre), Université Libre de Bruxelles (ULB) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Braine-l'Alleud Hospital | Braine-l'Alleud | 1420 | Belgium | |||
| CHU Saint-Pierre |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Hyperbaric prilocaine | Drug | intrathecal injection of 50 mg hyperbaric prilocaine 2% |
|
|
The levels of motor block will be determined at 5, 10, 20 and 30 minutes after intrathecal injection. The levels of motor block will be assessed by using the Bromage Scale (0=no motor block; 1=hip blocked; 2=hip and knee blocked; 3=hip, knee, and ankle blocked). |
| up to 30 minutes |
| Duration of motor block | Total duration of motor block is the interval time between the end of intrathecal injection and the complete recovery of motor block | Until complete regression of motor block |
| Pain assessed by Visual Analog Scale | Pain levels will be determined at the inflation of tourniquet, at the incision and every 10 minutes in the PACU (Post Anesthesia Care Unit). Visual Analog pain score (scale = 0 no pain; 10 = worst pain imaginable). | up to 24 hours |
| Side-effects (hypotension, bradycardia, urinary retention) | Assessed during and after intervention | up to 24 hours |
| Brussels Capital Region |
| 1000 |
| Belgium |